Stem cell therapy for heart failure

Cardiology in Review

Volumn 22, Issue 3, 2014, Pages 105-116

  Michler, Robert E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

bone marrow mononuclear cells; cardiac stem cells; clinical trials; endothelial progenitor cells; heart Failure

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR;

ACUTE HEART INFARCTION; ANGIOGENESIS; APOPTOSIS; CARDIAC STEM CELL; CELL LINEAGE; CELL REGENERATION; CELL THERAPY; CELL TRANSDIFFERENTIATION; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOBLAST; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PARACRINE SIGNALING; PATIENT SAFETY; REVIEW; STEM CELL TRANSPLANTATION; ANIMAL; BONE MARROW TRANSPLANTATION; ENDOTHELIUM CELL; HEART DISEASES; TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL CELLS; HEART DISEASES; HUMANS; MYOBLASTS; STEM CELL TRANSPLANTATION;

EID: 84898599924     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000018     Document Type: Review

References (107)

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197.
2. Murphy SL, Xu JQ, Kochanek KD. Deaths: Preliminary data for 2010. National vital statistics reports; vol 60 no 4. Hyattsville, MD: National Center for Health Statistics. 2012.
3. Killip T, Passamani E, Davis K. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68:939-950
4. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin. 2001;19:547-555.
5. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
6. Baumgartner WA, Burrows S, del Nido PJ, et al; National Heart, Lung, and Blood Institute Working Group on Future Direction in Cardiac Surgery Recommendations of the National Heart, Lung, and Blood Institute Working Group on Future Direction in Cardiac Surgery. Circulation. 2005;111:3007-3013.
7. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107-S112.
8. Thom T, Haase N, Rosamond W, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
9. Terrovitis J Bulte JW, Sarvananthan S, et al. Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells seeded on collagen scaffolds-relevance to tissue engineering. Tissue Eng. 2006;12:2765-2775.
10. Lenzen MJ, Boersma E, Reimer WJ, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26:2706-2713.
11. MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol. 2000;62:289-319.
12. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multi-potent and support myocardial regeneration. Cell. 2003;114:763-776.
13. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fbroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(suppl):365-371.
14. Thompson S, Clarke AR, Pow AM, et al. Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells. Cell. 1989;56:313-321.
15. Rolletschek A, Blyszczuk P, Wobus AM. Embryonic stem cell-derived cardiac, neuronal and pancreatic cells as model systems to study toxicological effects. Toxicol Lett. 2004;149:361-369.
16. Boheler KR, Czyz J, Tweedie D, et al. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res. 2002;91:189-201.
17. Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001;108:407-414.
18. Xu C, Police S, Rao N, et al. Characterization and enrichment of cardiomyo-cytes derived from human embryonic stem cells. Circ Res. 2002;91:501-508.
19. Min JY, Yang Y, Converso KL, et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol (1985). 2002;92:288-296.
20. Min J Y, Huang X, Xiang M, et al. Homing of intravenously infused embryonic stem cell-derived cells to injured hearts after myocardial infarction. J Thorac Cardiovasc Surg. 2006;131:889-897.
21. Nelson TJ, Ge ZD, Van Orman J, et al. Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. Anat Rec A Discov Mol Cell Evol Biol. 2006;288:1216-1224.
22. Riess P, Molcanyi M, Bentz K, et al. Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors. J Neurotrauma. 2007;24:216-225.
23. Mauro A. Satellite cell of skeletal muscle fbers. J Biophys Biochem Cytol. 1961;9:493-495.
24. Rumyantsev P P. Some comparative aspects of myocardial regeneration. In: Muscle Regeneration, edited by A. Mauro et al., New York: Raven Press; 1979:335-355.
25. Menasché P, Hagège AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41:1078-1083.
26. Ferreira-Cornwell MC, Luo Y, Narula N, et al. Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart. J Cell Sci. 2002;115(pt 8):1623-1634.
27. Perriard JC, Hirschy A, Ehler E. Dilated cardiomyopathy: a disease of the intercalated disc? Trends Cardiovasc Med. 2003;13:30-38.
28. Iijima Y, Nagai T, Mizukami M, et al. Beating is necessary for transdiffer-entiation of skeletal muscle-derived cells into cardiomyocytes. FASEB J. 2003;17:1361-1363.
29. Formigli L, Francini F, Tani A, et al. Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment. Am J Physiol Cell Physiol. 2005;288:C795-C804.
30. Reinecke H, MacDonald GH, Hauschka SD, et al. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol. 2000;149:731-740.
31. Ohno N, Fedak PW, Weisel RD, et al. Transplantation of cryopreserved muscle cells in dilated cardiomyopathy: effects on left ventricular geometry and function. J Thorac Cardiovasc Surg. 2003;126:1537-1548.
32. Pouly J, Hagège AA, Vilquin JT, et al. Does the functional effcacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy? Circulation. 2004;110:1626-1631.
33. McConnell PI, del Rio CL, Jacoby DB, et al. Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure. J Thorac Cardiovasc Surg. 2005;130:1001.
34. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005;112:1748-1755.
35. Menasché P. Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure. J Cardiovasc Transl Res. 2008;1:201-206.
36. Antman EM. Coronary care medicine: it's not your father's CCU anymore. Trans Am Clin Climatol Assoc. 2004;115:123-134; discussion 134.
37. Dimmeler S, Zeiher AM. Cell therapy of acute myocardial infarction: open questions. Cardiology. 2009;113:155-160.
38. Larochelle A, Vormoor J, Hanenberg H, et al. Identifcation of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 1996;2:1329-1337.
39. Michallet M, Philip T, Philip I, et al. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitu-tion. Exp Hematol. 2000;28:858-870.
40. Kawashima I, Zanjani ED, Almaida-Porada G, et al. CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Blood. 1996;87:4136-4142.
41. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
42. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defning mul-tipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
43. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fbroblast colony-forming cells (CFU-F) and their progeny. Blood. 1980;56:289-301.
44. Tang YL, Zhao Q, Zhang YC, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 2004;117:3-10.
45. Arai F, Hirao A, Suda T. Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol. 2005;82:371-376.
46. Furness SG, McNagny K. Beyond mere markers: functions for CD34 family of sialomucins in hematopoiesis. Immunol Res. 2006;34:13-32.
47. Ferreri NR, Escalante BA, Zhao Y, et al. Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol. 1998;274(1 pt 2):F148-F155.
48. Mezey E, Chandross KJ, Harta G, et al. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science. 2000;290:1779-1782.
49. Lagasse E, Connors H, Al-Dhalimy M, et al. Purifed hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229-1234.
50. Fukuhara S, Tomita S, Yamashiro S, et al. Direct cell-cell interaction of car-diomyocytes is key for bone marrow stromal cells to go into cardiac lineage in vitro. J Thorac Cardiovasc Surg. 2003;125:1470-1480.
51. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697-705.
52. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-98.
53. Sussman MA, Murry CE. Bones of contention: marrow-derived cells in myo-cardial regeneration. J Mol Cell Cardiol. 2008;44:950-953.
54. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modifed with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195-1201.
55. Tang J, Xie Q, Pan G, et al. Mesenchymal stem cells participate in angio-genesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg. 2006;30:353-361.
56. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-397.
57. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.
58. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20.
59. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
60. Wollert KC, Meyer G P, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-148.
61. Meyer G P, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113:1287-1294.
62. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mono-nuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355:1199-1209.
63. Schachinger V, Erbs S, Seeger FH, et al. Improved clinical outcome after intra-coronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: fnal 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775-2783.
64. Assmus B, Tonn T, Seeger FH, et al. Red blood cell contamination of the fnal cell product impairs the effcacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol. 2010;55:1385-1394.
65. Wöhrle J, Merkle N, Mailänder V, et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol. 2010;105:804-812.
66. Tendera M, Wojakowski W, Ruzyłło W, et al; REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30:1313-1321.
67. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesen-chymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286.
68. Plewka M, Krzeminska-Pakuła M, Lipiec P, et al. Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol. 2009;104:1336-1342.
69. Gyöngyösi M, Lang I, Dettke M, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med. 2009;6:70-81.
70. Chen SL, Fang W W, Ye F, et al. Effect on left ventricular function of intracoro-nary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92-95.
71. Sürder D, Schwitter J, Moccetti T, et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI). Am Heart J. 2010;160:58-64.
72. Traverse JH, Henry TD, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308:2380-2389.
73. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mono-nuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306:2110-2119.
74. Jeevanantham V, Butler M, Saad A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126:551-568.
75. Wen Y, Chen B, Wang C, et al. Bone marrow-derived mononuclear cell therapy for patients with ischemic heart disease and ischemic heart failure. Expert Opin Biol Ther. 2012;12:1563-1573.
76. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-2302.
77. Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004;110(11 suppl 1):II213-II218.
78. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation. 2006;114(1 suppl):I101-I107.
79. Assmus B, Honold J, Schächinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355:1222-1232.
80. Assmus B, Fischer-Rasokat U, Honold J, et al; TOPCARE-CHD Registry. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res. 2007;100:1234-1241.
81. Flores-Ramírez R, Uribe-Longoria A, Rangel-Fuentes MM, et al. Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insuf-fciency. Cardiovasc Revasc Med. 2010;11:72-78.
82. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12:721-729.
83. Stamm C, Kleine HD, Choi YH, et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic isch-emic heart disease: safety and effcacy studies. J Thorac Cardiovasc Surg. 2007;133:717-725.
84. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379.
85. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endo-thelial cells for angiogenesis. Science. 1997;275:964-967.
86. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343-353.
87. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothe-lial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-293.
88. Giannotti G, Doerries C, Mocharla PS, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension. 2010;55:1389-1397.
89. Sieveking D P, Buckle A, Celermajer DS, et al. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol. 2008;51:660-668.
90. Gruh I, Beilner J, Blomer U, et al. No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation. 2006;113:1326-1334.
91. Sinha S, Poh KK, Sodano D, et al. Safety and effcacy of peripheral blood progenitor cell mobilization and collection in patients with advanced coronary heart disease. J Clin Apher. 2006;21:116-120.
92. Zohlnhöfer D, Dibra A, Koppara T, et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol. 2008;51: 1429-1437.
93. Erbs S, Linke A, Adams V, et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: frst randomized and placebo-controlled study. Circ Res. 2005;97:756-762.
94. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115:3165-3172.
95. Dawn B, Stein AB, Urbanek K, et al. Cardiac stem cells delivered intravas-cularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci USA. 2005;102:3766-3771.
96. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95:911-921.
97. Bearzi C, Leri A, Lo Monaco F, et al. Identifcation of a coronary vascular progenitor cell in the human heart. Proc Natl Acad Sci USA. 2009;106:15885-15890.
98. Urbanek K, Quaini F, Tasca G, et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:10440-10445.
99. Anversa P, Kajstura J, Leri A, et al. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006;113:1451-1463.
100. Anversa P, Rota M, Urbanek K, et al. Myocardial aging-a stem cell problem. Basic Res Cardiol. 2005;100:482-493.
101. Lanza R, Moore MA, Wakayama T, et al. Regeneration of the infarcted heart with stem cells derived by nuclear transplantation. Circ Res. 2004;94:820-827.
102. D'Alessandro DA, Kajstura J, Hosoda T, et al. Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart. Circ Res. 2009;105:1128-1140.
103. Davis DR, Zhang Y, Smith RR, et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One. 2009;4:e7195.
104. Malliaras K, Marbán E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull. 2011;98:161-185.
105. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115:896-908.
106. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.
107. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895-904.